Physician profile
Holly C Mathis
NPI 1720062607
$2,412.68
in general payments reported to CMS, 2019-2025
15 companies · $957 in 2025
The $957 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.93 · 2023: $377 · 2024: $982 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $592.54 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Amgen INC. | $274.24 | 2023-2024 | Evenity, Repatha |
| Abbvie INC. | $250.17 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $179.45 | 2023-2025 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Alkermes, INC. | $122.07 | 2024 | Vivitrol |
| Edwards Lifesciences Corporation | $120.13 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Glaxosmithkline, LLC. | $120.03 | 2025 | Shingrix |
| Genzyme Corporation | $109.86 | 2025 | |
| Corcept Therapeutics | $106.49 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.93 | 2021 | |
| Vertos Medical, INC. | $94.28 | 2024 | Mild Device Kit |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $86.38 | 2025 | |
| Viiv Healthcare Company | $74.33 | 2025 | Apretude |
| Sanofi-Aventis U.S. LLC | $60.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.